<DOC>
	<DOCNO>NCT01818648</DOCNO>
	<brief_summary>We plan examine gastrointestinal ( GI ) physiologic profile Exenatide , glucagon-like peptide ( GLP-1 ) analog possible intestino-trophic growth factor capable induce small bowel adaptation regeneration patient short bowel syndrome ( SBS ) , potential decrease parenteral nutrition dependence .</brief_summary>
	<brief_title>Exenatide GI Motor Function Permeability Short Bowel Syndrome</brief_title>
	<detailed_description />
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Short Bowel Syndrome</mesh_term>
	<mesh_term>Mannitol</mesh_term>
	<mesh_term>Lactulose</mesh_term>
	<mesh_term>Glucagon-Like Peptide 1</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Patients short bowel syndrome , age 1885 dependent parenteral nutrition least year closely follow Mayo Clinic Home Parenteral Nutrition Program ( HPN ) least one multisystem evaluation year .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>85 Years</maximum_age>
	<verification_date>January 2014</verification_date>
</DOC>